The preclinical study demonstrated that the combination of roflumilast (PDE4 inhibitor) and cobimetinib (MEK inhibitor) can suppress the proliferation of patient‐derived NRASQ61 melanoma in vitro [327]. This evidence concerns the gene MAP2K7 and melanoma.